Chai Discovery, the company engineering AI models to discover new molecules, today announced a license agreement with leading biopharmaceutical company Pfizer.

The agreement will enable Pfizer to deploy Chai's AI platform as part of its drug discovery engine, gaining early access to the Chai-3 model as well as a custom model that leverages Pfizer's proprietary data and is tailored to Pfizer's workflows.